BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - FRA:IDP - US09062X1037 - Common Stock
121.55 EUR
+0.05 (+0.04%)
We assign a fundamental rating of 5 out of 10 to IDP. IDP was compared to 75 industry peers in the Biotechnology industry. While IDP has a great health rating, its profitability is only average at the moment. IDP has a bad growth rate and is valued cheaply. These ratings would make IDP suitable for value investing!
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
Each year in the past 5 years IDP has been profitable.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
IDP has a Return On Assets of 5.40%. This is in the better half of the industry: IDP outperforms 77.33% of its industry peers.
Looking at the Return On Equity, with a value of 8.68%, IDP is in the better half of the industry, outperforming 78.67% of the companies in the same industry.
The Return On Invested Capital of IDP (9.52%) is better than 85.33% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 13.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP has a Profit Margin of 15.31%. This is amongst the best in the industry. IDP outperforms 81.33% of its industry peers.
IDP's Profit Margin has declined in the last couple of years.
IDP has a Operating Margin of 27.35%. This is amongst the best in the industry. IDP outperforms 85.33% of its industry peers.
In the last couple of years the Operating Margin of IDP has declined.
With a decent Gross Margin value of 75.43%, IDP is doing good in the industry, outperforming 68.00% of the companies in the same industry.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
Compared to 1 year ago, IDP has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.05 indicates that IDP is not in any danger for bankruptcy at the moment.
IDP has a Altman-Z score of 3.05. This is in the better half of the industry: IDP outperforms 72.00% of its industry peers.
IDP has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as IDP would need 3.40 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.40, IDP belongs to the top of the industry, outperforming 82.67% of the companies in the same industry.
IDP has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IDP (0.36) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.05 |
ROIC/WACC1.04
WACC9.17%
2.3 Liquidity
A Current Ratio of 2.50 indicates that IDP has no problem at all paying its short term obligations.
IDP's Current ratio of 2.50 is in line compared to the rest of the industry. IDP outperforms 53.33% of its industry peers.
IDP has a Quick Ratio of 1.79. This is a normal value and indicates that IDP is financially healthy and should not expect problems in meeting its short term obligations.
IDP has a Quick ratio of 1.79. This is comparable to the rest of the industry: IDP outperforms 46.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.61%.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
The Revenue has been growing slightly by 3.36% in the past year.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
The Earnings Per Share is expected to grow by 1.26% on average over the next years.
The Revenue is expected to decrease by -0.33% on average over the next years.
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.26%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.33%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IDP is valuated reasonably with a Price/Earnings ratio of 8.96.
Based on the Price/Earnings ratio, IDP is valued cheaper than 93.33% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 8.90 indicates a reasonable valuation of IDP.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.00% of the companies listed in the same industry.
IDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.71.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.96 | ||
| Fwd PE | 8.9 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 90.67% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaply inside the industry as 92.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.39 | ||
| EV/EBITDA | 7.06 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (9/16/2025, 7:00:00 PM)
121.55
+0.05 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.67%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap17.82B
Analysts72.86
Price Target146.58 (20.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)-1.54%
PT rev (3m)-4.57%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)-3.55%
EPS NY rev (1m)6.04%
EPS NY rev (3m)5.87%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)4.46%
Revenue NY rev (3m)4.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.96 | ||
| Fwd PE | 8.9 | ||
| P/S | 2.1 | ||
| P/FCF | 11.39 | ||
| P/OCF | 9.94 | ||
| P/B | 1.19 | ||
| P/tB | 12.57 | ||
| EV/EBITDA | 7.06 |
EPS(TTM)13.56
EY11.16%
EPS(NY)13.65
Fwd EY11.23%
FCF(TTM)10.67
FCFY8.78%
OCF(TTM)12.23
OCFY10.06%
SpS57.75
BVpS101.87
TBVpS9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.05 |
F-Score6
WACC9.17%
ROIC/WACC1.04
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.26%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.33%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year9.29%
EBIT Next 3Y4.38%
EBIT Next 5Y5.37%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%